Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
Compounds of Formulae I' and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
所述式 I' 和 I 的化合物可用作 sGC 的刺激剂,特别是 NO 依赖性、血红素依赖性刺激剂。这些化合物还可用于治疗、预防或控制本文公开的各种疾病。
sGC stimulators
申请人:Ironwood Pharmaceuticals, Inc.
公开号:US10183021B2
公开(公告)日:2019-01-22
Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
本文描述了式 I′ 和 I 的化合物,它们可用作 sGC 的刺激剂,特别是 NO 依赖性、血红素依赖性刺激剂。这些化合物还可用于治疗、预防或控制本文公开的各种疾病。
USE OF SGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
申请人:IRONWOOD PHARMACEUTICALS, INC.
公开号:US20160324856A1
公开(公告)日:2016-11-10
The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising a sGC stimulator or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for the treatment of a neuromuscular disorder associated with loss or alteration of function of nitric oxide synthase (NOS).